Breaking News Instant updates and real-time market news.

CRL

Charles River

$98.36

-1.24 (-1.25%)

08:45
08/09/17
08/09
08:45
08/09/17
08:45

Charles River says sees FY17 free cash flow $265M-$275M

Sees FY17 CapEx $75M-$85M.

  • 09

    Aug

CRL Charles River
$98.36

-1.24 (-1.25%)

05/12/17
RHCO
05/12/17
NO CHANGE
RHCO
Charles River weakness unjustified, says SunTrust
SunTrust analyst Sandy Draper believes that Charles River reported "solid" results.He thinks investors are worried that the company's lower than expected Discovery and Safety Assessment revenue "indicates a cycle top for early-stage research." The analyst disagrees with this assessment ,partly because of the company's "rapidly accelerating bookings growth in March." He thinks the stock's weakness has created a good buying opportunity and keeps a $105 price target on the name.
02/15/17
BARD
02/15/17
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $89 at Baird
Baird analyst Eric Coldwell raised his price target on Charles River Labs to $100 from $89 as he said the company is firing on all cylinders. He believes the shares have room to run as the valuation is not stretched and secular trends and catalysts are ahead. Coldwell reiterated his Outperform rating on Charles River shares.
02/14/17
BARD
02/14/17
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $89 at Baird
Baird analyst Eric Coldwell raised Charles River's price target to $100 following the Q4 beat and guidance. Coldwell reiterates his Outperform rating and said valuation isn't stretched and secular trends and catalysts are favorable.
01/04/17
01/04/17
UPGRADE
Target $86.5

Buy
Charles River upgraded to Buy on robust demand, earnings growth at Evercore ISI
As previously reported, Evercore ISI upgraded Charles River to Buy from Hold and with an $86.50 price target. Analyst Ross Muken said his upgrade hinges on three key items, robust biopharma demand is likely to continue and benefit discovery/early development, fears of margin degradation from a mix shift are overblown, and management has a stellar capital allocation track record that has led to significant TSR. Muken adds Charles River's current discount provides a favorable entry point for investors looking for upside from double digit earnings growth.

TODAY'S FREE FLY STORIES

WERN

Werner

$30.95

-0.1 (-0.32%)

13:27
08/17/17
08/17
13:27
08/17/17
13:27
Hot Stocks
Werner CEO says business has been improving throughout the year »

The trucking firm's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:25
08/17/17
08/17
13:25
08/17/17
13:25
General news
U.S. VIX equity volatility surged 26% to 14.88 highs »

U.S. VIX equity…

13:25
08/17/17
08/17
13:25
08/17/17
13:25
Conference/Events
SEC holds a closed commission meeting »

Closed Commission Meeting…

WMT

Wal-Mart

$79.18

-1.7998 (-2.22%)

13:24
08/17/17
08/17
13:24
08/17/17
13:24
Recommendations
Wal-Mart analyst commentary  »

Wal-Mart posted good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

ADP

ADP

$111.10

-0.48 (-0.43%)

13:21
08/17/17
08/17
13:21
08/17/17
13:21
Recommendations
ADP analyst commentary  »

ADP will have difficulty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

NAK

Northern Dynasty

$1.56

0.065 (4.36%)

13:20
08/17/17
08/17
13:20
08/17/17
13:20
Options
Call buyers back in Northern Dynasty Minerals »

Call buyers back in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.55

-0.035 (-0.30%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Upgrade
Celestica rating change  »

Follow-up: Celestica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

, AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Hot Stocks
Breaking Hot Stocks news story on Tesaro, AstraZeneca »

Tesaro drops 2% after FDA…

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

$NSD

NASDAQ Market Internals

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.11

-0.07 (-0.24%)

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Hot Stocks
FDA posts approval of new dosage form for AstraZeneca's Lynparza 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 08

    Sep

$NYE

NYSE Market Internals

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:13
08/17/17
08/17
13:13
08/17/17
13:13
Hot Stocks
CenturyLink says working to finalize Level 3 deal by end of Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:12
08/17/17
08/17
13:12
08/17/17
13:12
Hot Stocks
Breaking Hot Stocks news story on CenturyLink, Level 3 »

CenturyLink says working…

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

13:10
08/17/17
08/17
13:10
08/17/17
13:10
Options
ADP attracts put buyers as shares come under fire »

ADP attracts put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADOM

Adomani

$12.86

0.86 (7.17%)

, VLKAY

Volkswagen

$31.10

0.19 (0.61%)

13:06
08/17/17
08/17
13:06
08/17/17
13:06
Hot Stocks
Adomani sees $2.9B in settlement funds from Volkswagen »

Adomani (ADOM) announced…

ADOM

Adomani

$12.86

0.86 (7.17%)

VLKAY

Volkswagen

$31.10

0.19 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.89

-0.05 (-0.42%)

13:05
08/17/17
08/17
13:05
08/17/17
13:05
Options
Horizon Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.50

-0.08 (-0.69%)

13:04
08/17/17
08/17
13:04
08/17/17
13:04
Upgrade
Celestica rating change  »

Celestica upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$0.95

0.05 (5.56%)

12:55
08/17/17
08/17
12:55
08/17/17
12:55
Hot Stocks
Medovex names Charlie Farrahar as CFO »

Medovex reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$33.20

-0.16 (-0.48%)

12:53
08/17/17
08/17
12:53
08/17/17
12:53
Hot Stocks
FDA posts approval of Pfizer's biologic license qpplication for Besponsa 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

NADL

North Atlantic Drilling

$1.44

-0.075 (-4.97%)

12:50
08/17/17
08/17
12:50
08/17/17
12:50
Options
Notable put spread in North Atlantic Drilling »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

12:45
08/17/17
08/17
12:45
08/17/17
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

HRB

H&R Block

$30.21

-0.53 (-1.72%)

12:40
08/17/17
08/17
12:40
08/17/17
12:40
Options
Higher option volume in H&R Block driven by call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 14

    Sep

EXPE

Expedia

$148.78

1.72 (1.17%)

12:35
08/17/17
08/17
12:35
08/17/17
12:35
Options
Expedia put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
08/17/17
08/17
12:35
08/17/17
12:35
General news
Treasury Option Action: call buying at the long-end »

Treasury Option Action:…

ADP

ADP

$111.10

-0.48 (-0.43%)

12:32
08/17/17
08/17
12:32
08/17/17
12:32
Hot Stocks
Chapman says making dollar going against Ackman feels as good as $10 »

Robert Chapman of Chapman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.